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REVIEW CURRENTOPINION Irritable bowel syndrome, inflammatory bowel
disease and the microbiomeCopyright © Lippincott W
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The review aims to update the reader on current developments in our understanding of how the gut
microbiota impact on inflammatory bowel disease and the irritable bowel syndrome. It will also consider
current efforts to modulate the microbiota for therapeutic effect.
Recent findings
Gene polymorphisms associated with inflammatory bowel disease increasingly suggest that interaction with
the microbiota drives pathogenesis. This may be through modulation of the immune response, mucosal
permeability or the products of microbial metabolism. Similar findings in irritable bowel syndrome have
reinforced the role of gut-specific factors in this ‘functional’ disorder. Metagenomic analysis has identified
alterations in pathways and interactions with the ecosystem of the microbiome that may not be recognized
by taxonomic description alone, particularly in carbohydrate metabolism. Treatments targeted at the
microbial stimulus with antibiotics, probiotics or prebiotics have all progressed in the past year. Studies on
the long-term effects of treatment on the microbiome suggest that dietary intervention may be needed for
prolonged efficacy.
Summary
The microbiome represents ‘the other genome’, and to appreciate its role in health and disease will be as
challenging as with our own genome. Intestinal diseases occur at the front line of our interaction with the
microbiome and their future treatment will be shaped as we unravel our relationship with it.
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bowel syndrome (IBS) both present with diarrhoea,
abdominal pain, accelerated transit and altered diet.
They share a number of common causative features
including genetic predispositions, impaired gut bar-
rier function and altered microbiota, which will be
the focus of this review.
In the past 10 years, the revolution in the speed
and cost of gene sequencing has made it possible to
enumerate and quantify the human microbiota:
bacteria and other organisms that live in and around
the human body over half of which were previously
unculturable and hence unknown. The vast
majority of these, estimated at 1014 organisms, live
in the colon, and in this review will be referred to as
the microbiota.
INFLAMMATORY BOWEL DISEASE
Genetic associations have proliferated in the past
few years and a recent meta-analysis of genome-
wide association studies reported 163 susceptibility
loci, including 71 new associations [1
&&
]. That theilliams & Wilkins. Unau
Health | Lippincott Williams & WilkiATG16L1 and IL23R, contribute to pathways for
detecting, responding to and processing of micro-
biota, has emphasized the likely importance of
host–microbial interactions in causing disease. Of
note, Iliev et al. [2
&&
] have recently reported a single-
nucleotide polymorphism (SNP) in the CLEC7A
gene associated with treatment-resistant ulcerative
colitis. This gene codes for dectin-1, a C-type lectin
receptor that recognizes commensal gut fungi [2
&&
].
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CKEY POINTS
 Changes in the intestinal microbiota have been found
in both IBD and IBS.
 Proliferation of the phylum Proteobacteria, with
reduction in Firmicutes, is observed in
intestinal inflammation.
 Diet, particularly fat and indigestible carbohydrates,
has been shown to influence microbiota and gut health,
but how this translates into symptom experience
is unclear.
 Antibiotics and faecal transplantation are potential
therapies for intestinal inflammation and functional
symptoms, but the durability of this effect in the context
of a potentially pathogenic diet is uncertain.
Gastrointestinal hormonestype developed more severe dextran sodium sul-
phate (DSS) colitis, with increased tissue invasion,
an effect prevented by the antifungal fluconazole.
The earlier findings that lower levels of Faecali-
bacterium prausnitzii on the ileal mucosa of patients
with Crohn’s disease was associated with recurrent
disease, and that F. prausnitzii could induce inter-
leukin (IL)-10 in vitro with reduced inflammation in
mouse models of colitis [3] introduced the concept
that specific elements of the microbiota might
modify inflammation.
Recent studies have confirmed lower levels of
F. prausnitzii in adults with both Crohn’s disease [4
&
]
and ulcerative colitis [5], but this is not essential and
may be just a marker of an abnormal microbiota. A
recent study which looked at new cases of paediatric
Crohn’s disease actually found increased F. prausni-
tizii in mucosal biopsies associated with reduced
bacterial diversity [6
&
]. However, relatives of patients
with ulcerative colitis without disease also have
reduced F. prausnitizii [5], suggesting that this might
relate to genetic factors which in animals clearly
influence the microbiota (for review, see [7
&&
]). That
this is also true in humans is supported by Li et al.
[8
&
] who demonstrated lower levels of Clostridium
group IV in biopsies of resected ileum from ileal
Crohn’s disease patients without the NOD2 risk
allele though interpretation is difficult owing to
confounding by treatments including perioperative
antibiotics. Clearer results can be seen in mouse
models of ileitis (Toxoplasma gondii infection and
indomethacin) in which inflammation leads to
marked loss in diversity in ileal mucosal biopsies,
with reduction in Firmicutes, replaced by Proteo-
bacteria, including the adherent and invasive Escher-
ichia coli (AIEC) [9
&&
]. NOD2 deletion was associated
with reduced numbers of Firmicutes in uninfected
mice, and after infection a dramatic shift to 99.8%opyright © Lippincott Williams & Wilkins. Unautho
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impairing antibacterial defences. These effects were
somewhat reduced by anti-tumour necrosis factor
(TNF) antibody therapy. Smoking, the environmen-
tal factor most associated with Crohn’s disease, has
also been linked to a higher proportions of Bacter-
oides–Prevotella in faeces [4
&
]. Oral microbiota in
Crohn’s disease patients, but not ulcerative colitis
patients, show reduced diversity with reduced
Firmicutes and Fusobacteria and an increase in
Bacteroidetes [10
&
]. A recent paediatric studywas able
to discriminate patients with IBD from other diag-
noses on the basis of microbiota testing alone [11
&&
].
Morgan et al. [12
&&
] inferred the microbiome
from the microbiota in a sample of 121 Crohn’s
disease and 75 ulcerative colitis patients, and 27
healthy controls. Ileal Crohn’s disease showed the
greatest difference from controls with 12% of the
metagenomic pathways analysed significantly
affected. IBD patients had lower levels of Rumino-
coccaceae and Roseburia, metabolically interlinked
clades both known to produce short-chain fatty
acids (SCFAs) (acetate from Ruminococcaceae utilized
by Roseburia to produce butyrate), whereas Faecali-
bacterium, a major butyrate producer, was again
reduced in ileal Crohn’s disease, compared to an
abundance of Escherichia. 5-Aminosalicylate use was
associated with reductions in Escherichia, whereas
antibiotic use, greatest in ulcerative colitis, was
associated with greatly reduced diversity. Metage-
nomic profiles showed that IBD microbiomes,
particularly in ileal Crohn’s disease, had reduced
capacity for amino acid biosynthesis and carbo-
hydrate metabolism, with increased presence of
enzymes to metabolize mucin, and transport carbo-
hydrate and sulphate. Erickson et al. [13
&
] used a
multi‘omics’ approach in six twin pairs from the
Swedish twin cohort, both concordant and discor-
dant for disease. They confirmed reduced levels of
Faecalibacterium, as well as reduced richness of the
microbiota in Crohn’s disease, most markedly with
ileal disease. Analysis of the proteome showed
reduced abundance of genes for CAZymes, enzymes
capable of degrading complex carbohydrates typical
of plant cell walls, though since dietary data were
unavailable, it is not clear whether this is due to
patient selection of a low fibre diet in an attempt to
minimize symptoms [13
&
]. The increased presence,
however, of Omp proteins, found on gram-negative
bacteria, does suggest a shift to a microbiota more
able to elicit a proinflammatory response through
Toll-like receptor (TLR)-4 signalling.
IRRITABLE BOWEL SYNDROME
Some of the most convincing observational data for
an interaction between the microbiome and IBSrized reproduction of this article is prohibited.
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IBS, IBD and the microbiome Major and Spillersymptoms comes from studying Campylobacter
enteritis which markedly increases gut permeability
and leads to IBS in around 10%. Swan et al. [14
&
]
looked at mucosal gene expression both 6 months
after C. jejuni infection and in IBS and identified
several common alterations compared to healthy
controls, including increased TNFSF15mRNA. They
went on to examine candidate genes whose expres-
sion was shown to be abnormal in both patient
groups and confirmed a recent report [15] of an
increase in the major allele of a TNFSF15 SNP associ-
ated with diarrhoea-predominant IBS, and also
identified a TNF-a polymorphism associated with
postinfectious IBS. A HapMap showed that the
TNFSF15 SNPs in the two studies are closely linked
so they can be regarded as replications. A meta-
analysis of studies preceding this report found an
increased incidence of polymorphisms associated
with lower levels of IL-10 in IBS, though the small
numbers even in the meta-analysis mean these
studies need replication [16].
Another similarity between IBS and IBD is the
association of both with increased mucosal per-
meability. IL-22 is recognized to regulate mucosal
permeability and its secretion ismodulated by IL-23,
a recognized risk factor for IBD. IL-22-deficient mice
have recently been shown to have altered commen-
sal microbiota with an increased presence of Proteo-
bacteria, and reduced Firmicutes [17
&&
]. They
developed more severe colitis in a noninfectious
model, and were able to transmit this exaggerated
response to co-housed wild-typemice, whosemicro-
biota also included the Proteobacteria seen in the
knockouts. IL-22 dysfunction has also been linked
to increases in circulating antibodies to enteric
pathogens in IBD [18
&
]. Several studies show IBS is
associated with increased permeability (for review,
see [19]). Martinez et al. [20
&&
,21
&&
] examined the
underlying mechanism showing structural defects
by electronmicroscopy along with down-regulation
of the tight junction protein ZO1 at both gene and
protein level in jejunal biopsies from IBS patients
with diarrhoea. Abnormalities of faecal microbiota
in IBS reported in several series are inconsistent
probably because confounders such as diet, smok-
ing, age and antibiotic use have not been adequately
controlled for. Better controlled intervention
studies are needed to overcome this defect, so the
report that faecal microbiota transplant from IBS
patients into gnotobiotic mice can induce visceral
hypersensitivity is a step in the right direction [22
&&
].
The authors transplanted themicrobiota of three IBS
patients with constipation (IBS-C) and two healthy
controls into germ-free mice. They showed a
reduction in bifidobacteria and increase in Enter-
obacteriaceae and sulphate-reducing bacteria withCopyright © Lippincott Williams & Wilkins. Unau
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production with IBS microbiota compared to con-
trols. This profile was similar to these authors’
previous report in 14 IBS-C patients and 12 healthy
controls using selective culture techniques to
enumerate bacteria divided into anaerobes, hydro-
lytic (using a range of substrates including cellulose,
xylan, spinach, wheat), H2-consuming and lactate-
utilizing bacteria [23]. They showed no difference in
hydrolytic bacteria, but a decrease in lactate-utiliz-
ing bacteria (mainly Bifidobacteria and Lactobacilli),
and 100-fold increase in sulphate-reducing bacteria.
Ex-vivo fermentation experiments confirmed the
IBS microbiota produced less butyrate but strikingly
more sulphide. H2S is now recognized to be an
important neurotransmitter causing hypersensitiv-
ity to colonic distension and might be a mediator of
the microbiota influence. Bile acids can also sensi-
tize the gut to distension. Faecal primary bile acids
are increased in both colonic IBD [24
&
] and IBS [25
&
]
compared to healthy controls, possibly due to a
reduction in metabolism caused by acceleration of
colonic transit or by an abnormal microbiota. Inter-
estingly, secondary bile acids exert an anti-inflam-
matory effect via the bile acid-specific membrane
receptor TGR5, and the authors suggest that this loss
of anti-inflammatory effects might be important for
inflammation in IBD.
Microbiota may exert an influence on motility
via activation of TLRs as shown by the finding that
mice deficient in TLR4, a pathogen recognition
receptor targeted to lipopolysaccharide (LPS), and
its downstream signalling molecule MyD88 both
show loss of nitrergic neurones and slower intestinal
transit [26
&
].
Understanding of the role of microbiota in IBS
has been summarized recently [7
&&
], but the number
of studies is limited. The largest study to date from
Finland [27] found that by using 129 genus-like
markers within the 16sRNA gene, they could dis-
tinguish the microbiota of healthy individuals from
IBS patients. Firmicutes dominated, but the ratio of
Firmicutes : Bacteroidetes was higher in IBS who had
lower levels of Bifidobacteria and a slight increase in
Gammaproteobacteria. There was a negative corre-
lation with overall symptom score for some genus-
like groups such as Faecalibacterium and Eubacterium
rectale, but positive correlation with Gammaproteo-
bacteria. Jeffery et al. [28
&&
] used a smaller Swedish
cohort (37 mixed-type IBS patients compared to 20
healthy individuals). They identified three clusters
of IBS patients based on their microbiota, two of
which had significant increases in Firmicutes/
Bacteroidetes ratio and were distinct from controls,
whereas the other 15/37 clustered with the micro-
biota of healthy individuals. The rates of clinicallythorized reproduction of this article is prohibited.
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CGastrointestinal hormonessignificant depressionwere 2/22 (9%) in the first two
IBS groups, but 6/15 (40%) in those with normal-like
microbiota, suggesting that patients without disor-
deredmicrobiota may have more social and psycho-
logical drivers to their condition [28
&&
]. A recent
paediatric study found no differences in phyla
between 22 children with IBS and diarrhoea, and
22 healthy controls [29], but with these numbers no
definitive conclusions are possible.
MANIPULATING THE MICROBIOTA:
ANTIBIOTIC, PROBIOTIC, PREBIOTIC
Two large randomized placebo-controlled trials in
IBS patients showed a small therapeutic benefit with
rifaximin, a nonabsorbable rifamycin antibiotic [30]
[number needed to treat (NNT)¼10], suggesting
that a disordered microbiota, or ‘dysbiosis’, might
be important, although whether that dysbiosis is
present in the small bowel or colon is unclear. A
recent study examined the effect of two courses of
ciprofloxacin in three individuals. Whereas overall
numbers of bacteria fell 1–2 logs, some bacteria were
suppressed, whereas others increased. The response
was mostly short-lived, but some permanent
changes were noted which cautions against the
widespread use of antibiotics [31]. Antibiotic treat-
ment leads to an increase in antibiotic resistance
phages [32
&
] and increased susceptibility to patho-
gens such as Clostridum difficile.
These complications have encouraged interest
in alternative methods of manipulation, one of the
most extreme being faecal transplantation. A recent
systematic review reported 317 cases of recurrent
C. difficile infection treated across 27 case series with
a success rate of 92% [33]. This has been confirmed
by a recent randomized controlled trial (RCT) of
nasojejunal faecal infusion against standard antimi-
crobial therapy [34
&&
], which backed up impressive
clinical outcomes (NNT <2) with data showing the
recovery of patients’ microbiotal diversity to levels
comparable with faeces donors. Transplantation of a
normal microbiome to treat C. difficile infection in
an otherwise normal bowel aims to re-establish
normal colonization resistance with a persistently
altered microbiota. IBD and IBS are both, however,
chronic diseases with persistent abnormalities of
function which may well alter the transplanted
microbiota making its establishment more difficult.
A systematic review of the evidence base for faecal
transplant in IBD found nine reports and no con-
trolled trials [35], but showed some promising data,
though much less convincing than for C. difficile,
given the expected placebo response of 13–24% [36].
Devkota et al. [37
&&
] elegantly showed that diets
containing saturated milk fat, but not polyunsatu-
rated vegetable oil, increased the percentage of totalopyright © Lippincott Williams & Wilkins. Unautho
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change promoted the growth of the pathobiont
Bilophila wadsworthia, which induced a colitis in
mice deficient in IL-10 [37
&&
]. The interaction
between diet and microbiome is illustrated in
humans by Smith et al. [38
&
] who found that Mala-
wian children who developed kwashiorkor on their
usual diet had a disordered microbiota compared to
their healthy twins, and that a diet with higher
energy availability could change themicrobiota, pre-
venting as well as resolving disease. Wu et al. [39]
showed that dietary change canalter themicrobiome
within a day, but that enterotype is more stable and
correlates better with long-term dietary habits.
Children in rural Africa have a microbiota very
significantly different to that of urban European
children [40] related to the substantially greater fibre
intake (predominantly the nonabsorbable xylans
and cellulose) and reduced dairy and meat intake
in Africa. The discovery that SCFAs could regulate
the enteroendocrine and immune response via
G-protein-coupled receptor 43 (GPR43/FFAR2),
and that oral acetate could attenuate DSS colitis
which was worse in the absence of commensal
microbiota [41], indicated that these microbial
metabolic products exert an anti-inflammatory
effect. This is mediated via the GPR43 receptor as
the attenuation was absent inGpr43 knockout mice.
SCFA are also known to affect enteric neurons,
increasing cholinergic neurones and increasing
motility [42]. An RCT of 30 days of a poorly digested
carbohydrate supplement in obese women showed a
significant increase in stool Firmicutes, including
F. prausnitzii, with a reduction in Propionibacteria
and some Bacteroides [43
&
]; however, there was no
effect on the numerous metabolic parameters
measured. There has been a report of the benefit
of an elemental diet in nine patients with pouchitis
with nonsignificant increase in selected Firmicutes,
but this needs repeating with larger numbers [44].
One case report showed normalization of micro-
biota in a patient with Crohn’s disease treated
successfully with an elemental diet of protein and
fat, encouraging further larger studies [45].
Patients with IBS often report improvement
with diets excluding high-fibre foods, and diets
reducing intake of fermentable carbohydrates,
labelled low FODMAP diets, have proved popular
[46]. There may be a role for restricting FODMAPs
after gastroenteritis since mice were less able to clear
a pathogen and reconstitute their microbiota when
polysaccharides were available than when they were
replaced with simple sugars, a manoeuvre which
may force commensals to compete with pathogens
[47
&&
]. Kashyap et al. [48
&&
], using gnotobiotic mice
with and without a humanized microbiome,rized reproduction of this article is prohibited.
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FIGURE 1. The overlapping factors that influence IBD, IBS and the microbiome. Schematic representation of the factors that
contribute to IBD and IBS. Dashed lines represent pathways requiring further evidence. Barrier function and permeability may
be the key to pathogenesis in both disorders and be the critical factor in mucosal interaction with the microbiota. Most
relationships with the microbiota will be bidirectional, increasing the complexity of understanding its effects. IBD, inflammatory
bowel disease; IBS, irritable bowel syndrome.
IBS, IBD and the microbiome Major and Spillershowed not only that microbiota alter transit but
that transit alters the microbiota, making it clear
that inferring causation from association will be
particularly problematic in this field.
CONCLUSION
The microbiome is potentially readily manipulated
for therapeutic benefit. However, translating pre-
clinical progress to bedside intervention will need
larger studies than are currently available to provide
the needed power, given the large number of vari-
ables which alter outcome. Since diet seems to be the
overriding factor in the long-term stability of the
microbiota, methodologically rigorous evaluation
of diet will be important. Both IBD and IBS have
uncertain cause and the insights gained from this
investigative process will undoubtedly shed new
light on their genesis and reveal new approaches
to prevention, as well as treatment (Fig. 1).
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